Embla Medical hf

Embla Medical hf

26.20
DKK
+0.15
(+0.58%)
1.38EPS
19.49P/E
11.41BMarket Cap
Feb 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.97
1.13
1.09
1.19
1.32
1.44
1.62
1.49
1.7
1.72
1.87
2
2.18
2.31
Basic EPS, GAAP
0.09
0.13
0.12
0.12
0.13
0.19
0.16
0.01
0.15
0.1
0.14
0.16
0.2
0.21
Free Cash Flow per Basic Share
0.11
0.15
0.09
0.09
0.13
0.09
0.15
0.16
0.17
0.08
0.09
0.18
0.23
0.21
Dividend per Share
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
- -
- -
- -
- -
- -
- -
Book Value per Share
0.99
1
1.04
1.07
1.17
1.26
1.34
1.36
1.47
1.51
1.67
1.82
2.08
2.16
Tangible Book Value per Share
- -
0.03
0.13
0.06
0.09
-0.04
-0.05
-0.23
-0.19
-0.25
-0.13
-0.22
-0.12
-0.01
Basic Weighted Avg Shares
450
450
444
439
431
426
423
422
422
418
420
427
427
423
Sales/Revenue/Turnover
436
509
483
521
569
613
686
630
719
719
786
855
929
980
Operating Margin (%)
13.8
16.87
15.99
13.83
13.17
13.55
14.21
8.46
13.31
9.34
11.13
13.19
13.43
13.25
Depreciation Expense
15
18
20
22
23
28
44
65
52
49
50
56
61
62
Net Income, GAAP
40
59
51
51
58
80
66
6
64
43
58
68
83
89
Effective Tax Rate (%)
25.93
23.6
25.33
25.46
16.12
17.64
23.7
37.73
24.22
23.08
22.64
23.85
22.51
22.42
Profit Margin (%)
9.28
11.67
10.61
9.8
10.14
13.01
9.62
0.99
8.9
5.92
7.43
7.99
8.97
9.08
Working Capital
92
92
97
97
105
156
166
179
132
112
180
188
148
94
LT Debt
130
122
84
130
133
222
337
448
381
394
424
447
446
352
Total Equity
448
442
463
467
500
538
569
577
627
636
705
781
896
926
Return on Invested Capital (%)
7.97
11.08
10.17
9.07
9.67
8.99
8.66
1.76
6.89
4.53
5.98
6.91
7
7.12
Return on Capital (%)
7.74
10.68
9.59
9.09
9.42
11.56
8.17
1.05
6.53
4.6
6.28
6.95
7.22
7.45
Return on Common Equity (%)
9.49
13.4
11.35
10.99
11.93
15.42
12.02
1.09
10.72
6.76
8.73
9.23
9.99
10.36

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
96
189
182
LT Borrowings
292
212
205
LT Finance Leases
153
152
147
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
428
427
426
Market Capitalization
2,187
1,751
1,745

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
458
451
467
Cash, Cash Equivalents & STI
103
94
99
Accounts Receivable, Net
145
141
152
Inventories
166
166
162
Total Current Liabilities
310
373
373
Payables & Accruals
- -
- -
- -
ST Debt
96
189
182
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.91%
9.28%
14.74%
Free Cash Flow
16.87%
18.98%
30.51%
Net Income, GAAP
91.57%
194.52%
22.05%
Sales/Revenue/Turnover
- -
- -
8.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
200
217
214
225
855
2025
203
232
- -
257
929
2026
232
259
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.05
0.05
0.04
0.16
2025
0.03
0.05
- -
0.06
0.2
2026
0.03
0.07
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Sveinn Sölvason
Full Time Employees
4,192
Sector
Health technology
Industry
Medical specialties
Address
Grjothals 1-5 Reykjavík SU Iceland 055412
IPO Date
Jan 1, 2009
Business
Embla Medical hf. engages in the design, manufacture, and distribution of non-invasive orthopedic products and related patient care services. The company focuses on prosthetics and neuro-orthotics, bracing and supports, and patient care solutions, delivering an end-to-end ecosystem from product development to clinical delivery. Its products include lower- and upper-limb prosthetics, microprocessor-controlled and bionic components, neuro-orthotic joints, and a range of spinal, hip, knee, foot, ankle, and hand braces and supports; it also operates orthotic and prosthetic clinics and patient care networks to support rehabilitation and functional outcomes. Founding year and headquarters - Founded in 2005, Embla Medical hf is headquartered in Reykjavik, Iceland, with operations expanding across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region through its member brands and subsidiaries. Core business model and structure - Core segments include Prosthetics and Neuro Orthotics (mechanical and advanced electronic components for limb loss and differences, including microprocessor-controlled devices and neuro-orthotic solutions), Bracing and Supports (spinal, hip, knee, foot, ankle, and hand devices; injury recovery and post-operative supports), and Patient Care (prosthetics and orthotics services delivered through clinics and networks). Latest major company changes - In the past two years, Embla Medical hf advances Growth'27 through strategic acquisitions and market expansion, most notably acquiring a majority stake in Streifender ortho.production to broaden its full-range offerings, strengthen geographic reach, and enhance service delivery in key markets. - The company continues to report progress on its strategic initiatives, including organic growth and selective acquisitions to augment portfolio breadth and clinical delivery capabilities, as highlighted in its 2025 annual results and Growth'27 framework. Geographic footprint and markets - Operates across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific, serving hospitals, clinics, orthotics and prosthetics retailers, and direct care networks; targets clinicians and patients requiring prosthetic, neuro-orthotic, bracing, and rehabilitation solutions. Subsidiaries and relationships - Embla Medical hf operates through a network of brands and subsidiaries aligned under its end-to-end platform, incorporating established orthotics and prosthetics brands and clinics to deliver integrated products and patient care services; the parent structure emphasizes cohesive product development and clinic-based care pathways. Customer focus and value proposition - Serves healthcare providers and patients requiring advanced prosthetic and orthotic solutions, with emphasis on improving mobility, gait, and functional outcomes through integrated devices, clinical delivery, and postoperative rehabilitation support. The company positions itself as a full-range provider from device innovation to patient care services, aiming for scalable growth through geographic expansion and strategic investments.

Company News

  • Embla Medical hf. (OSSUY) Q3 2026 Earnings Call Transcript

  • Embla Medical hf. (OSSUY) Q2 2026 Earnings Call Transcript

  • Embla Medical hf. (OSSUY) Q1 2026 Earnings Call Transcript

  • Embla Medical hf. (OSSUY) Q4 2025 Earnings Call Transcript

  • Embla Medical hf. (OSSUY) Q3 2025 Earnings Call Transcript

  • Embla Medical hf: Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH